1. Home
  2. IZEA vs TCRX Comparison

IZEA vs TCRX Comparison

Compare IZEA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

HOLD

Current Price

$4.26

Market Cap

74.9M

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.29

Market Cap

75.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
TCRX
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.9M
75.7M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
IZEA
TCRX
Price
$4.26
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
50.9K
1.3M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
12.28
EPS
N/A
N/A
Revenue
$20,099,695.00
$10,325,000.00
Revenue This Year
$20.81
N/A
Revenue Next Year
$14.86
$19.81
P/E Ratio
$54.43
N/A
Revenue Growth
N/A
266.65
52 Week Low
$1.79
$0.88
52 Week High
$5.86
$2.57

Technical Indicators

Market Signals
Indicator
IZEA
TCRX
Relative Strength Index (RSI) 62.26 59.37
Support Level $4.31 $0.93
Resistance Level $4.65 $1.96
Average True Range (ATR) 0.19 0.10
MACD 0.01 0.02
Stochastic Oscillator 74.74 59.63

Price Performance

Historical Comparison
IZEA
TCRX

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: